MEDFORD, Mass. - TelAve -- Travera Inc. Announces CLIA Approval of First-of-Its-Kind Blood Test to Assess Personalized Functional Response to Cancer Immunotherapy

Medford, MA — July 14, 2025 — Travera, a leader in functional precision oncology, today announced that its novel Travera NOVA™ test has received CLIA certification for clinical use. Travera NOVA is the first and only CLIA-certified blood-based assay that directly measures a patient's systemic immune response to multiple immune checkpoint inhibitors, offering new functional insights to guide immunotherapy selection.

Checkpoint inhibitors have revolutionized cancer treatment, but predicting which patients will benefit from these therapies remains a significant clinical challenge. Travera NOVA addresses this need with a rapid, label-free, single-cell assay that functionally assesses the health and responsiveness of a patient's immune cells— specifically T cells—using just a blood draw.

"We believe this marks the beginning of a new era in immunotherapy decision-making," said Mark Stevens, Ph.D., co-founder and CEO.

More on TelAve News

• Artbound: "The Cheech" Awarded Two 2025 LA Area EMMY Awards — Honored in ARTS & MUSIC COMPOSITION
• Rising Conservative Star Jordan Brace Emerges as Influential Political Voice with Elite Washington Connections
• Conservative Latinos for PA Shaping the Future of Hispanic Community, Guest State Treasurer Stacy Garrity
• Chasing Creative Plants Roots in Palm Coast, Builds Marketing Systems for Modern B2B Brands
• David M. White, DDS Celebrates 500 Five-Star Reviews in Reno

Unlike traditional biomarkers that focus on tumor characteristics such as PD-L1 expression or tumor mutational burden (TMB), Travera NOVA evaluates the functional vitality of circulating T cells, which are key mediators of anti-tumor activity. In early clinical studies, Travera NOVA has demonstrated >75% accuracy (AUC 0.78) in predicting response to immune checkpoint therapy, with performance improving further when paired with standard tumor biomarkers like tumor mutation burden (TMB) profiling.

Rob Kimmerling, Ph.D., co-founder and CTO noted, "By providing functional, real-time insight into immune cell response, Travera NOVA offers oncologists a new tool to better personalize treatment decisions—especially when facing multiple clinically accepted immunotherapy options."

Travera NOVA may be particularly useful in settings where oncologists must choose between multiple FDA approved immunotherapy options—for example, pembrolizumab vs. nivolumab, or single-agent PD-1 therapy vs. dual-agent regimens including CTLA-4 blockade. In these scenarios, Travera NOVA can help identify which treatment elicits the strongest immune response in that specific patient.

More on TelAve News

• BJ Simmons Releases Trapped In
• Advantai Group & One NZ launch groundbreaking Mobile solution to supercharge brand loyalty in NZ
• Shincheonji Reaches World-Class Level At International Taekwondo Competition
• TNT Removal & Disposal Celebrates Record Year Helping Pennsylvania Property Owners Reclaim Space
• SpaceWERX selects New Frontier Aerospace to Develop Bifröst Orbit Transfer Spacecraft

Available Now Through Early Access - Travera NOVA is currently available through Travera EarlyAccess™ for eligible cancer patients and clinical partners. The test requires only a simple blood draw and delivers results within 3 business days.

About Travera - Travera helps oncologists make more informed treatment decisions through its revolutionary cancer therapy guidance platform. Using a proprietary single-cell measurement technology initially invented at MIT, Travera provides real-time, ex vivo insights into how a patient's tumor or immune cells respond to different drugs. Travera's portfolio includes the 2-day RapidSelection™ test and now the blood-based NOVA immune vitality assay—helping patients identify their best next option, faster.

To learn more or inquire about early access email: info@travera.com or http://www.travera.com